Merck & Co.

Merck & Co. is an American multinational pharmaceutical company known as MSD outside the United States and Canada. It develops and sells prescription medicines, vaccines, and animal-health products.

Keytruda: Pembrolizumab is an antibody medicine that helps the immune system recognize and attack certain cancers. This cancer immunotherapy became one of Merck's best-known products and a major source of revenue.
Emanuel Merck: Emanuel Merck was a German pharmacist and chemist who developed the Merck family's pharmaceutical business in Darmstadt. His family business is the historical origin of the name later used by the American company.
Drug discovery: Drug discovery identifies and develops candidate substances that may prevent or treat disease. Merck's research begins by finding and testing potential medicines and vaccines.
Pharmaceutical industry: The pharmaceutical industry researches, develops, manufactures, and sells medicines. Merck is a large company within this global industry.
Gardasil: Gardasil is a vaccine that protects against several types of human papillomavirus. The vaccine is a signature Merck product for preventing HPV-related cancers.
Merck Group: Merck Group is a German science and technology company descended from the Merck family business. The German company and Merck & Co. separated after World War I and are now distinct corporations.
Clinical trial: A clinical trial is a study in people that evaluates a medical intervention's safety or effectiveness. Merck must test candidate products in human studies before seeking approval.
Pharmaceutical pricing: Pharmaceutical pricing is the setting and negotiation of prices for medicines. The cost and affordability of Merck medicines place the company in pricing debates.
Mectizan: Mectizan is the brand name for ivermectin used to treat river blindness and certain other parasitic infections. Merck's donation program made this medicine central to efforts against river blindness.
George W. Merck: George W. Merck led Merck & Co. as its president from 1925 to 1950. His leadership shaped the American firm's research-centered identity.

Linked from 9 pages